atorvastatin + pantoprazole

Atorvastatin + pantoprazole is a combination of two small molecule drugs frequently co-prescribed for patients who require both cholesterol management and gastric acid suppression. Atorvastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular risk, while pantoprazole is a proton pump inhibitor (PPI) that decreases gastric acid secretion for conditions such as GERD or peptic ulcer disease. Both drugs are metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19. Co-administration may alter their pharmacokinetics due to protein binding displacement or metabolic competition, potentially increasing the plasma concentration of atorvastatin and the risk of statin-associated adverse effects such as myopathy. This combination does not have a unique brand name formulation but represents concurrent use in clinical practice[1][2][4][5].